WhiteLab Genomics
WhiteLab Genomics is a Paris-based TechBio company that builds the ALFRED AI platform to rationally design viral vectors, payloads, and bioprocesses for gene and cell therapies, serving pharmaceutical firms, biotechs, and academic research institutions across Europe and North America.
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What WhiteLab Genomics does
WhiteLab Genomics is a Paris-headquartered TechBio company, founded in 2019 by David Del Bourgo and Julien Cottineau, that builds computational tools to accelerate the design and development of genomic medicines. The company serves pharmaceutical companies (Sanofi through the WIDGeT project, Cytiva), biotech firms (Siren Biotechnology, Carbon Biosciences), and academic research institutions (INSERM ART-TG, Généthon, Institut Imagine, Institut de La Vision, UMass Chan Medical School, Université de Sherbrooke), operating from offices in Paris, Boston, and Montréal. Its commercial proposition is to replace trial-and-error experimental screening in gene and cell therapy R&D with data-driven rational design of viral vectors (AAV, lentivirus), non-viral vectors (lipid nanoparticles), payloads, and bioprocesses.
The company's core offering is ALFRED (AI-Led Framework for Rational Exploration in Drug design), a proprietary platform composed of named sub-modules: Jenn.AI for biomarker mapping and target/receptor identification, Carl.AI for protein and vector engineering, Emma.AI for predictive modeling, Kate.Data and Dave.Data for proprietary data curation, and OLIVIA, an LLM/RAG/knowledge-graph tool that structures heterogeneous lentiviral vector bioprocess data. The platform uses ESM-2 protein language models, reinforcement learning, generative AI, and predictive analytics over a proprietary biomarker atlas covering 1,000+ datasets and 850+ cell types. WhiteLab has generated in-house assets including more than 1.2 million unique 3D peptide structures with an 8.3% validated hit rate, and in May 2026 disclosed in vivo data showing ALFRED-designed vectors achieving approximately 50-fold higher DNA enrichment in mouse brain versus AAV9 with no detectable liver signal after IV injection.
WhiteLab operates a co-development business model. Revenue is generated through funded research collaborations, milestone-based co-development agreements with pharmaceutical and biotech partners, and technology licensing of its platform components; pricing is quote-based and not publicly disclosed. The company is privately held following a $10 million Series A in September 2022 led by Debiopharm Innovation Fund with participation from Omnes Capital, layered on top of Y Combinator W22 backing and French government support through French Tech 2030 and the French Tech Health20 program. Headcount is disclosed only as a band of 11–50 across three offices, and the company has received industry recognition including Galien Foundation Best Startup finalist status in 2023.
WhiteLab Genomics firmographics
Firmographics- Name
- WhiteLab Genomics
- Legal name
- WhiteLab Genomics SAS
- Website
- https://whitelabgx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- WhiteLab Genomics is a Paris-based TechBio company that builds the ALFRED AI platform to rationally design viral vectors, payloads, and bioprocesses for gene and cell therapies, serving pharmaceutical firms, biotechs, and academic research institutions across Europe and North America.
- Ownership category
- akta.pro rank
WhiteLab Genomics industry classification
Industry- Product category
- AI-Driven Genomic Medicine Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where WhiteLab Genomics is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
WhiteLab Genomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Co-development and Research Partnerships: WhiteLab Genomics operates a co-development business model centered on strategic collaboration with academic and industrial partners. Revenue is generated through funded research collaborations, co-development agreements, and service contracts where partners pay for AI-driven genomic medicine design and optimization services.
- Technology Licensing and Platform Access: The company licenses access to its proprietary ALFRED AI platform and its component tools (Jenn.AI, Carl.AI, Emma.AI, etc.) to pharmaceutical and biotech partners for specific therapeutic programs.
- Collaborative R&D Programs: Ongoing collaborations with pharmaceutical companies such as Sanofi, Cytiva, and Carbon Biosciences generate revenue through milestone-based payments tied to research progress and successful delivery of AI-designed vectors and payloads.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
WhiteLab Genomics product offering
Product offeringCore offering
WhiteLab Genomics develops and operates the ALFRED AI platform, an AI-Led Framework for Rational Exploration in Drug design that combines advanced algorithms, curated proprietary biological databases, and computational biology to optimize therapeutic candidates for gene and cell therapy programs. The platform supports target receptor identification, viral vector design (AAV, lentivirus), non-viral vector design (lipid nanoparticles), payload design, and bioproduction optimization through co-development engagements with pharmaceutical companies, biotechs, and academic institutions.
Differentiator
Problem solved
Functional benefit
Brands
- ALFRED Platform: Proprietary AI-led Framework for Rational Exploration in Drug design - combines advanced algorithms, curated databases, and cutting-edge computational biology to optimize therapeutic candidates
- Kate.Data
- Jenn.AI
- Dave.Data
- Carl.AI
- Emma.AI
Products and services
- ALFRED Platform Proprietary AI platform for rational, in silico design of gene and cell therapy vectors and payloads, combining multiple AI/ML modalities with curated biological databases to accelerate and de-risk genomic medicine development for pharmaceutical companies, biotechs, and academic institutions.
- OLIVIA — Lentiviral Vector Downstream Processing Tool LLM-powered analytics tool that uses Retrieval-Augmented Generation and knowledge graphs to structure heterogeneous lentiviral vector downstream processing data, enabling automated process benchmarking and analysis for bioproduction teams.
- Co-Development & Research Partnership Services
Quantifiable outcome
- 3.5x higher success rate of entering Phase 1 compared to standard approach
- +4 more outcomes
Companies that use WhiteLab Genomics
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
WhiteLab Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature9 records
WhiteLab Genomics partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered core and supporting.
- UMass Chan Medical SchoolcorePartnership to use AI to optimize genomic medicines for neurological diseases. Professor Qinglan Ling's lab collaborates with WhiteLab to accelerate development of safer, more effective gene therapies for mitochondrial diseases and complex neurological and metabolic conditions.
- Cytiva (Expanded Collaboration)coreExpanded partnership with Cytiva to use AI to accelerate cell line development, combining WhiteLab's computational biology capabilities with Cytiva's manufacturing infrastructure.
- Carbon BiosciencescoreCollaboration to engineer novel genomic medicines and create new disease area opportunities using WhiteLab's ALFRED AI platform, with a focus on developing innovative vectors and expanding into previously inaccessible therapeutic areas.
- SanoficoreThrough the WIDGeT project, Sanofi collaborates with WhiteLab Genomics and academic partners (TarGeT Lab at Nantes University, Institut Imagine) to create novel AAV vectors with tropisms to hard-to-reach cells. Sanofi is the Global Head of Genomic Medicine and has invested in this collaboration to optimize delivery vehicles for nucleic acid medicines.
- CytivacoreStrategic collaboration combining Cytiva's biopharmaceutical manufacturing experience with WhiteLab's AI technology to help manufacturers reach clinical and regulatory milestones faster, benefiting patients globally.
- Siren BiotechnologysupportingPartnership to accelerate Siren's mission to develop universal immuno-gene therapies for cancer. WhiteLab's AI expertise in genomic medicine will be leveraged to identify new indications for AAV gene therapies using a novel AI-accelerated approach.
- Institut ImaginesupportingCollaboration integrating AI into the development and optimization of gene therapies. Institut Imagine contributes expertise in podocytopathies and innovative technological devices to enhance gene therapy effectiveness, demonstrating the importance of public-private, multidisciplinary collaborations.
- Institut de La VisionsupportingPartnership through the GEAR (Gene therapy Engineering with AI for Retina) project to apply AI-guided rational design for next-generation AAV vectors targeting retinal diseases. Dr. Deniz Dalkara leads research on developing viral vectors with the goal of significant impact on retinal and visual health.
- GénéthonsupportingCollaboration using WhiteLab's AI tools to review thousands of sequences and devise innovative combinations to develop a new generation of more specific AAV vectors for neuromuscular disorders. Part of the GenoTher Biocluster industry partnership.
- INSERM (ART-TG)supportingCollaboration with Anne Galy's team at ART-TG (Accelerateur de Recherche sur les Technologies de Thérapie Génomique) to integrate large bodies of information on critical parameters and their interconnections, enabling rapid experiment adaptation and strategic project acceleration through AI.
- Université de SherbrookesupportingCollaboration with the Medicinal Chemistry Laboratory at the Pharmacology Institute of Sherbrooke (IPS) to develop peptides targeting new pharmacological targets and optimize viral vectors for genomic medicine, contributing expertise in pharmacology and physiology.
- Bayer Co.LabsupportingWhiteLab Genomics maintains an office at Bayer Co.Lab in Cambridge, MA, marking a key milestone in the company's international expansion and providing proximity to the Boston biotech ecosystem.
- Ginkgo Bioworks (Technology Network)supportingWhiteLab joined Ginkgo Bioworks' Technology Network, marking a major milestone in international expansion and connecting with Ginkgo's ecosystem of biotech technology providers.
- Future4CaresupportingWhiteLab Genomics is housed at Future4Care, a European ecosystem of multidisciplinary actors dedicated to digital health and a joint venture founded by Capgemini, Generali, Orange, and Sanofi. Future4Care provides the physical location for WhiteLab's Paris office and facilitates connections with pharma and startup ecosystems.
- AI for HealthsupportingCo-organizer of TechBio France 2024, the inaugural national event for the French TechBio ecosystem. AI for Health is a French open innovation ecosystem with international reach, bringing together key stakeholders in AI and healthcare.
- France BiotechsupportingCo-organizer of TechBio France 2024. France Biotech is the French health innovation association representing over 2,700 HealthTech companies and serves as a key interlocutor for public authorities on health innovation policy.
- France DeeptechsupportingCo-organizer of TechBio France 2024. France Deeptech unites deeptech players in France with nearly 300 members including investment funds, startups, and leading research centers.
- NIIMBL (National Institute for Innovation in Manufacturing Biopharmaceuticals)supportingMember of the NIIMBL consortium driving the future of biopharmaceutical manufacturing. WhiteLab contributes to the development and adoption of next-generation technologies that enhance efficiency, innovation, and patient well-being.
- NIST Genome Editing ConsortiumsupportingPart of the National Institute of Standards and Technology's Genome Editing Consortium, collaborating with industry, academia, and government stakeholders to establish rigorous standards and measurement solutions for advancing genome editing with precision and reliability.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
WhiteLab Genomics competitors and assessment
Company assessmentDirect peers
- Dyno Therapeutics: Applies machine learning to AAV capsid engineering for gene therapy, directly competing with WhiteLab's Carl.AI capsid design capabilities. Operates a partnership model with gene therapy developers and biopharma that is structurally similar to WhiteLab's co-development motion.
- Generate Biomedicines: Generative biology platform using ML to design novel protein therapeutics across multiple modalities. Overlaps directly with WhiteLab's generative AI and protein language model approaches for therapeutic design, including non-viral vector and payload engineering.
- BigHat Biosciences: AI/ML-guided antibody and protein engineering platform using wet-lab-in-the-loop design. Comparable to WhiteLab in combining generative AI, protein language models, and in silico design with experimental validation for biologic therapeutic discovery.
- Insitro: Machine learning-driven drug discovery company combining high-throughput biology with AI models to accelerate therapeutic development. Comparable enterprise AI-for-biologics platform with a co-development/partnership model targeting pharma.
Broad incumbents
- Recursion Pharmaceuticals: Large-scale AI-driven drug discovery platform using high-throughput experimental data and machine learning to identify novel therapeutics. A more broadly-scoped competitor operating a similar AI+biology platform model with significantly more capital.
- AbCellera: AI-enabled antibody discovery platform combining high-throughput screening, ML, and a partnership model with pharma. Comparable in using ML to accelerate biologic discovery and operating a partnership/licensing revenue model.
- Schrödinger: Computational chemistry and physics-based drug design platform with AI/ML-augmented molecular simulation. Comparable in offering computational tools that accelerate therapeutic design, but operates at significantly larger scale and in small-molecule as well as biologic modalities.
Emerging players
- Tessera Therapeutics: Gene writing technology company developing novel approaches to genomic medicine. Operates in the same genomic medicine development space as WhiteLab's partners and overlaps on the application side of AI-driven vector and therapeutic design.
- Cradle Bio: AI platform for protein engineering and design using generative ML models. Comparable to WhiteLab's protein language model and generative AI capabilities for biologics, though focused on broader protein design rather than gene therapy vectors specifically.
- Lantern Pharma: AI-driven oncology drug development company using machine learning to identify and develop targeted therapies. Comparable in applying AI/ML to accelerate therapeutic development in a partnership-aware model, though focused on oncology small molecules.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
WhiteLab Genomics social profiles
Digital presenceWhiteLab Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
WhiteLab Genomics leadership team
Management profileNumber of profiles
Profiles5 records
WhiteLab Genomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WhiteLab Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WhiteLab Genomics
What does WhiteLab Genomics do?
WhiteLab Genomics develops and operates the ALFRED AI platform, an AI-Led Framework for Rational Exploration in Drug design that combines advanced algorithms, curated proprietary biological databases, and computational biology to optimize therapeutic candidates for gene and cell therapy programs. The platform supports target receptor identification, viral vector design (AAV, lentivirus), non-viral vector design (lipid nanoparticles), payload design, and bioproduction optimization through co-development engagements with pharmaceutical companies, biotechs, and academic institutions.
Is WhiteLab Genomics a public or private company?
WhiteLab Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was WhiteLab Genomics founded?
WhiteLab Genomics was founded in 2019. It employs 11 to 50 people.
Where is WhiteLab Genomics based?
WhiteLab Genomics is headquartered in Paris, France, in the Europe region.
How does WhiteLab Genomics make money?
Three revenue lines are on record. Co-development and Research Partnerships are the primary driver. The others are technology Licensing and Platform Access and collaborative R&D Programs.
Who are WhiteLab Genomics's main competitors?
Direct peers on record are Dyno Therapeutics, Generate Biomedicines, BigHat Biosciences and Insitro. Broad incumbents are Recursion Pharmaceuticals, AbCellera and Schrödinger. Emerging players are Tessera Therapeutics, Cradle Bio and Lantern Pharma.
Does WhiteLab Genomics have an API?
No public API is recorded for WhiteLab Genomics.
What industry is WhiteLab Genomics in?
WhiteLab Genomics's product category is AI-Driven Genomic Medicine Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 8731.